Email to
Enter your name
Enter your email address
To read the publication please click here.
Regulatory and Industry Update: The Medicinal Cannabis Sector
ESMA updates EMIR Q&A and clarifies point on EMIR Refit calculation dates
ESMA Q&As on MiFID II/ MiFIR investor protection & intermediaries topics
ESMA consults on MiFIR alignment following the introduction of EMIR Refit
Cross-Border Pre-Marketing Regime applicable to AIFs